InspireMD paints its product recall as a short, manageable pause, but the latest update shows shifting timelines, job cuts, and key commercial details quietly disappearing. See what still looks solid, what keeps slipping, and what that could mean for the comeback story.Read more

Reddit’s shares drop hard even after what looks like a strong quarter, and the reason isn’t as simple as “the market is wrong.” The key question is whether a brewing fight with Google could hurt traffic and future deals—or end up strengthening Reddit’s hand for years.Read more

Hims & Hers pushes beyond weight loss by stacking new services like lab testing, hormone care, and international expansion on top of its fast-growing subscription base. A reset in weight-loss supply and new partnerships change what the business can sell—and the big question is whether this broader platform can keep momentum while it keeps spending heavily.Read more

Tempus AI is quietly turning genetic tests and clinical records into a healthcare data platform that drugmakers and hospitals can plug into, making the system more useful every time it’s used. With growth holding up, costs improving, and big-name funds taking notice, the bigger question is whether its debt and high expectations around AI could still trip it up.Read more

TransMedics helps doctors keep donated organs working longer outside the body, which could make more transplants possible as demand rises and hospitals modernize. The big question is whether it can keep improving the technology and expand overseas without getting slowed down by regulation, competition, or growing pains.Read more

Broadcom isn’t just riding the buzz around artificial intelligence—it sells the behind-the-scenes tech that keeps data moving, connected, and secure across modern computing. If the world keeps demanding more computing and networking over the coming years, Broadcom could benefit even if today’s AI leaders change.Read more

Meta is using artificial intelligence to make its apps not just addictive, but better at predicting what people want to buy—pushing it from “showing ads” toward taking a cut of shopping itself. That upside comes with big bets on new infrastructure, tougher regulation risks, and the question of whether all that spending really pays off.Read more

Lululemon’s growth story looks stuck just as shoppers and the market start treating the brand as yesterday’s news, even though the business still throws off a lot of cash and has room to grow outside North America. The key question is whether new leadership can refresh the products and protect the brand’s “cool” before rising competition, tariffs, and discounting do lasting damage.Read more

Robinhood could see a surge in trading if new rules make it easier for everyday people to day trade and if calmer headlines lift the mood in markets. But the same forces can swing the other way, and the business also depends heavily on what happens in crypto.Read more